Adaptive Servoventilation as Treatment for Central Sleep Apnea Due to High-Altitude Periodic Breathing in Nonacclimatized Healthy Individuals

• DOI: 10.1089/ham.2017.0147
• Publication Date: 2018-03-29T17:06:51Z
• Authors: Jeremy E. Orr; Erica C. Heinrich; Matea Djokic; Dillon Gilbertson; Pamela N. Deyoung; Cecilia Anza-Ramirez; Francisco C. Vill...; Frank L. Powell; Atul Malhotra; Tatum Simonson
• Keywords: Adult; Male; https://purl.org/pe-repo/ocde/ford#3.01.08; Sleep Apnea; Physiology; https://purl.org/pe-repo/ocde/ford#3.03.05; Acclimatization; Polysomnography; Clinical Sciences; Medical Physiology; 610; central sleep apnea; lung; 03 medical and health sciences; 0302 clinical medicine; Medical physiology; Cardiovascular Medicine and Haematology; 616; Humans; Oximetry; Interactive Ventilatory Support; Lung; Central; https://purl.org/pe-repo/ocde/ford#3.03.11; Biomedical and Clinical Sciences; Altitude; Respiration; noninvasive ventilation; Middle Aged; Respiration, Artificial; Sleep Apnea, Central; Healthy Volunteers; Oxygen; Treatment Outcome; Artificial; Female; Sleep Research; altitude

Orr, Jeremy E., Erica C. Heinrich, Matea Djokic, Dillon Gilbertson, Pamela N. Deyoung, Cecilia Anza-Ramirez, Francisco C. Villafuerte, Frank L. Powell, Atul Malhotra, and Tatum Simonson. Adaptive servoventilation as treatment for central sleep apnea due to high-altitude periodic breathing in nonacclimatized healthy individuals. High Alt Med Biol. 19:178-184, 2018.Central sleep apnea (CSA) is common at high altitude, leading to desaturation and sleep disruption. We hypothesized that noninvasive ventilation using adaptive servoventilation (ASV) would be effective at stabilizing CSA at altitude. Supplemental oxygen was evaluated for comparison.Healthy subjects were brought from sea level to 3800 m and underwent polysomnography on three consecutive nights. Subjects underwent each condition-No treatment, ASV, and supplemental oxygen-in random order. The primary outcome was the effect of ASV on oxygen desaturation index (ODI). Secondary outcomes included oxygen saturation, arousals, symptoms, and comparison to supplemental oxygen.Eighteen subjects underwent at least two treatment conditions. There was a significant difference in ODI across the three treatments. There was no statistical difference in ODI between no treatment and ASV (17.1 ± 4.2 vs. 10.7 ± 2.9 events/hour; p > 0.17) and no difference in saturation or arousal index. Compared with no treatment, oxygen improved the ODI (16.5 ± 4.5 events/hour vs. 0.5 ± 0.2 events/hour; p < 0.003), in addition to saturation and arousal index.We found that ASV was not clearly efficacious at controlling CSA in persons traveling to 3800 m, whereas supplemental oxygen resolved CSA. Adjustment in the ASV algorithm may improve efficacy. ASV may have utility in acclimatized persons or at more modest altitudes.